Nvidia-backed Iambic Therapeutics files for IPO, unveils AI-driven pipeline

Iambic Therapeutics, a San Diego biotech that uses artificial intelligence to discover medicines, announced it has filed a registration statement to become a publicly traded company.

The filing marks another milestone for the growing wave of AI-focused biotech startups and follows backing from Nvidia, which has invested in the company’s technology platform.

In its IPO prospectus the company provided new details about its pipeline, describing several preclinical programs that leverage AI models to identify novel targets and candidates.

The move signals Iambic’s intention to raise capital to advance its research and expand collaborations with pharmaceutical partners.